Expression of nectin-4 as a potential biomarker in enzootic nasal adenocarcinoma of goats

2016 ◽  
Vol 64 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Ahmet Aydoğan ◽  
Özlem Özmen

The aim of this study was to test nectin-4 by immunohistochemistry as a potential biomarker in enzootic nasal adenocarcinoma (ENA) of goats. Twentyfour archival ENA case samples [from 14 male and 10 female hair goats (Capra hircus)] were used. The samples were stained with haematoxylin and eosin (HE). Nectin-4 expression was studied by immunohistochemistry. By microscopy, tubular, papillary, and mixed patterns of ENA were diagnosed in the cases. Immunohistochemically, the tumours showed moderate nectin-4 expression (++) in 14 cases (58.3%), strong expression (+++) in five cases (20.8%), and weak expression (+) in three cases (12.5%), while two cases (8.3%) were negative. Normal nasal tissues were not stained with nectin-4. The results suggest that nectin-4 may be used as a valuable biomarker of ENA.

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2662-2662 ◽  
Author(s):  
Laurent Miguet ◽  
Luc Fornecker ◽  
Marie Wyrwas ◽  
Sarah Cianferani ◽  
Raoul Herbrecht ◽  
...  

Abstract Introduction Diagnosis of mature B-cells proliferations, especially those involving the spleen, do not always falls into any of the WHO types of B-cell neoplasms using standart diagnosis tools. This situation in notably encountered in the case of the differential diagnosis of marginal zone lymphoma (MZL), atypical chronic lymphocytic leukemia (aCLL), mantle cell lymphoma (MCL), and lymphoplasmacytic lymphoma (LPL), mostly due to the lack of immunological positive markers. In order to find new markers to discriminate between these different malignancies, we have previously developed a proteomic strategy based on the analyses of plasma membrane microparticles and proposed two new specific markers: CD148 and CD1801,2 for MCL and MZL respectively. The simultaneous use of these two markers, together with the CD200 that is positive in most cases of CLL and negative in MCL could be of great interest to better assess the differential diagnosis. Methods Flow cytometry analyses have been realized in Nancy and Strasbourg hospitals by combining these three markers: CD148 (Clone 143-41 FITC); CD180 (Clone G28.8 PE) and CD200 (Clone OX104 APC). Expression profile of these proteins was established on a well characterized set of patients (N=287): CLL with a Matutes score > 3 (N=81); MCL harboring t(11;14) translocation or CCND1 overexpression (N=44); LPL (N=58) classified following cytological morphology, IgM peak and the positivity of CD38 and/or Myd88 mutation, MZL (N=84), displaying a CD5- CD23- immunophenotype associated to a splenomegaly and 20 controls. For each group the mean of fluorescence intensity and Standard Error have been determined. Results MCL exhibited a strong expression of CD148 combined with a weak expression of CD180 and CD200. A weak expression of CD148 and CD180 coupled to a strong expression of CD200 was typical of the CLL group and a weak expression of CD148 and CD200 coupled to a strong expression of CD180 was observed in the MZL group. A moderate expression of these three markers was observed in the LPL group. A threshold corresponding to MFI +/- 4 standard error was then calculated for each group, and patients were categorized following the expression profile of these 3 markers (see figures). In this cohort, the above described profiles correctly identified MCL cases with a specificity of 92% and a sensitivity of 64%, aCLL cases with a specificity of 100% and a sensitivity of 47%, LPL cases with a specificity of 90% and a sensitivity of 54% and MZL cases with a specificity of 99% and a sensitivity of 60%. Conclusion These results strongly suggest that the incorporation of these three markers CD148 CD180 and CD200 in addition of the routinely used flow cytometry panel can be helpful in a number of cases for which the diagnosis is difficult. References: 1) Miguet et al leukemia 2013 2) Miguet et al journal of proteome research 2009 Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.


2017 ◽  
Vol 16 ◽  
pp. 1-13
Author(s):  
João Luiz de Miranda ◽  
Felipe Rodrigues de Matos ◽  
Frederico Santos Lages ◽  
Dhelfeson Willya Douglas-de-Oliveira ◽  
Roseana de Almeida Freitas

AIM: The aim was to compare the immunoexpression of extracellular matrix proteins in squamous cell carcinomas of tongue (SCCTo) and lower lip (SCCLi). METHODS: Eleven SCCTo and 11 SCCLi were selected and examined according to Bryne’s method (1998). For immunohistochemical study utilized antibodies to fibronectin, tenascin and type I collagen. Histopathologic and immunohistochemical analysis were performed on the tumor invasive front. RESULTS: All SCCTo were classified in high score malignant grade and all SCCLi in lower score. Fibronectin showed strong immunorreactivity in the peritumoral basement membrane (BM) in 91% of SCCTo and all cases of SCCLi, while in the tumor stroma (TS) all cases of SCCTo and SCCLi had strong intensity. Tenascin had strong expression in BM of 91% cases of SCCTo and 63.4% of SCCLi and in TS had strong expression in 91% cases of SCCTo and 54.6% of SCCLi. Type I collagen demonstrated weak immunoreactivity in the TS of 72.7% cases of SCCTo and 63.4% of SCCLi. CONCLUSION: These results may suggest that the strong expression of fibronectin and tenascin proteins and the weak expression of type I collagen could play a role in the invasive process of oral SCC.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3727-3727
Author(s):  
Marcus A. Stockschlaeder ◽  
Olga Shardakova ◽  
Boris Fehse ◽  
Rudiger E. Scharf

Abstract Blood endothelial outgrowth cells (BEOC), bone marrow derived cells circulating in adult peripheral blood, may play an important role in postnatal vasculogenesis. Overexpression of antithrombotic genes in BOEC might enhance thromboresistance and open new avenues for the treatment of prosthetic and vascular thromboembolic disease. To genetically modify endothelial progenitor cells (EPC), we have used two different culture conditions for the generation of EPC from peripheral blood. Mononuclear cells harvested from peripheral blood of healthy volunteers by Ficoll-density gradient centrifugation were cultured (1) in fibronectin (FN)-coated plates with Endocult medium or (2) in collagen-coated plates with EBM2-MV medium. Colonies were counted at day 5 or between days 14 – 25, respectively. Cells were phenotypically analyzed on days 7, 14, 21, 28 or between days 30 – 60, respectively, for the following antigens: leukocyte markers CD45 and CD14, and endothelial markers CD31, CD34, CD105, CD141, CD144, CD146, and von-Willebrand (vW) antigen. Stem cell microarray hybridization was used to analyze the gene expression pattern. Proliferative potential was evaluated by determination of replating efficiency, growth kinetics, and CFSE dilution analysis. Using nonadherent cells cultured on FN-coated plates, colonies appeared on days 4–5. They consisted of central round cells with elongated cells sprouting at the periphery. These cells slowly disappeared after days 8–10. FACS analysis of these cells showed strong expression of CD45 and CD14, weak expression of CD31, but no expression of CD105, CD34, and vW-antigen. Using cells adherent to collagen, cells appeared at a median of 20 ± 5 days (range 9 – 29 days). These cells rapidly formed colonies with a cobblestone-like appearance and subsequently a confluent monolayer. After a lag phase, cell expanded exponentially (21 population doublings in 50–60 days). These cells showed strong expression of CD31, CD105, and CD146, intermediate expression of CD141, weak expression of CD34, and no expression of CD45 or CD14. Cells stained positive for VE-cadherin and vW-antigen. Microarray analysis displayed upregulated expression of endothelial genes such as PAI-1, uPA, eNOS, vWF, CD105, CD141, CD144, CD146, EphrinB4, TIE-1, VEGF-R2, endothelin and other genes such as CTGF, MMP2, ID1, ID3, TBX1, GATA2, FKHL16, ROBO4, but downregulation of CD11c, CD18, and L-selectin. An eGFP-encoding retroviral SFFV vector (cell free supernatant from PG13; titer 1.5x106 cfu) and a novel lentiviral LeGO vector expressing the red chomophore tdTomato (cell-free supernatant from PhoenixGP or 293T, packaging plasmids pMDLg/pRRE, pRSV-Rev; GALV env; 16x106 cfu) were used for centrifugation-enhanced transduction. BEOC were transduced with high efficiency, 62% – 80% and 91% – 99%, using the murine retroviral SF-eGFP and the human LeGo-T lentiviral vectors, respectively. Our results suggest that nonadherent cells cultured on FN-coated plates have a low proliferative potential and display an angiogenic macrophage-like phenotype. In contrast, adherent cells cultured on collagen-coated plates have a high proliferative potential, display an endothelial phenotype without coexpression of leukocyte antigens, and can be very efficiently transduced using retroviral vectors. Blood endothelial outgrowth cells may be an excellent autologous biomaterial source for vascular graft and device coatings, as well as for antithrombotic gene therapy.


2006 ◽  
Vol 189 (2) ◽  
pp. 511-521 ◽  
Author(s):  
Kevin Dixon ◽  
Christopher D. Bayliss ◽  
Katherine Makepeace ◽  
E. Richard Moxon ◽  
Derek W. Hood

ABSTRACT Simple sequence repeats located within reading frames mediate phase-variable ON/OFF switches in gene expression by generating frameshifts. Multiple translation initiation codons in different reading frames are found upstream of most Haemophilus influenzae tetranucleotide repeat tracts, raising the possibility of multiple active reading frames and more than two levels of gene expression for these loci. Phase variation between three levels of gene expression (strong, weak, and none) was observed when lic2A was fused to a lacZ reporter gene. The lic2A 5′ CAAT repeat tract is preceded by four 5′ ATG codons (x, y, z1, and z2) in two reading frames. Each of these initiation codons was inactivated by site-directed mutagenesis. Strong expression from frame 1 was associated with x but not y. Weak expression from frame 2 was mainly dependent on the z2 codon, and there was no expression from frame 3. Using monoclonal antibodies specific for a digalactoside epitope of lipopolysaccharide whose synthesis requires Lic2A, two levels (strong and undetectable) of antibody reactivity were detected, suggesting that weak expression of lic2A is not discernible at the phenotypic level. Inactivation of the x initiation codon resulted in loss of strong expression of the digalactoside epitope and elevated killing by human serum. The failure to detect more than two phenotypes for lic2A, despite clear evidence of weak expression from the z1/z2 initiation codons, leaves open the question of whether or not multiple initiation codons are associated with more complex patterns of phenotypic variation rather than classical phase-variable switching between two phenotypes.


PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11905
Author(s):  
Kristina Jansen ◽  
Franziska Büscheck ◽  
Katharina Moeller ◽  
Martina Kluth ◽  
Claudia Hube-Magg ◽  
...  

Background DOG1 (ANO1; TMEM16A) is a voltage-gated calcium-activated chloride and bicarbonate channel. DOG1 is physiologically expressed in Cajal cells, where it plays an important role in regulating intestinal motility and its expression is a diagnostic hallmark of gastrointestinal stromal tumors (GIST). Data on a possible role of DOG1 in pancreatic cancer are rare and controversial. The aim of our study was to clarify the prevalence of DOG1 expression in pancreatic cancer and to study its association with parameters of cancer aggressiveness. Methods DOG1 expression was analyzed by immunohistochemistry in 599 pancreatic cancers in a tissue microarray format and in 12 cases of pancreatitis on large tissue sections. Results DOG1 expression was always absent in normal pancreas but a focal weak expression was seen in four of 12 cases of pancreatitis. DOG1 expression was, however, common in pancreatic cancer. Membranous and cytoplasmic DOG1 expression in tumor cells was highest in pancreatic ductal adenocarcinomas (61% of 444 interpretable cases), followed by cancers of the ampulla Vateri (43% of 51 interpretable cases), and absent in 6 acinus cell carcinomas. DOG1 expression in tumor associated stroma cells was seen in 76 of 444 (17%) pancreatic ductal adenocarcinomas and in seven of 51 (14%) cancers of the ampulla Vateri. Both tumoral and stromal DOG1 expression were unrelated to tumor stage, grade, lymph node and distant metastasis, mismatch repair protein deficiency and the density of CD8 positive cytotoxic T-lymphocytes in the subgroups of ductal adenocarcinomas and cancers of ampulla Vateri. Overall, the results of our study indicate that DOG1 may represent a potential biomarker for pancreatic cancer diagnosis and a putative therapeutic target in pancreatic cancer. However, DOG1 expression is unrelated to pancreatic cancer aggressiveness.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5407-5407
Author(s):  
Laurent Miguet ◽  
Caroline Mayeur-Rousse ◽  
Sarah Lennon ◽  
Luc Fornecker ◽  
Carine Gervais ◽  
...  

Abstract There are a number of small B-cell proliferations that do not fall into any of the types of B-cell neoplasms recognized in the WHO classification using classical immunophenotypic markers. This situation is notably encountered in the case of the differential diagnosis of marginal zone lymphoma (MZL), atypical chronic lymphocytic leukemia (aCLL) mantle cell lymphoma (MCL) or lymphoplasmacytic lymphoma (LPL). This is mostly due to the lack of immunological specific markers especially when histological samples are not available or during leukemic phases of atypical B-cell neoplasms. In order to find new markers to discriminate between these different malignancies, we have previously developed a proteomic strategy based on the analyses of plasma membrane microparticles and proposed two new specific markers: CD148 and CD1801, 2 for MCL and MZL respectively. The simultaneous use of these two markers, together with the CD200 that is positive in most cases of CLL and negative in MCL3 could be of great interest to better assess the differential diagnosis. In the present study, we report the results obtained by the combination of the three markers studied in addition to the routine flow cytometry panel: CD148 (Clone 143-41 FITC); CD180 (Clone G28.8 PE) and CD200 (Clone OX104 APC). An expression profile of these proteins have been established on a well characterized set of patients: CLL with a Matutes score > 3 (N=28); MCL harboring t(11;14) translocation or CCND1 overexpression (N=20); LPL (N=16) classified following cytological morphology, IgM peak and positivity of CD38, and MZL (N=27), displaying a CD5- CD23-immunophenotype associated to a splenomegaly. For each group the mean of fluorescence intensity and Standard Error have been determined. MCL patients exhibited a strong expression of CD148 (MFI = 1480) combined with a weak expression of CD180 and CD200 (MFI = 888 and 426 respectively). A weak expression of CD148 and CD180 (MFI = 495 and 754) coupled to a strong expression of CD200 (MFI = 3750) was typical of the CLL group and a weak expression of CD148 and CD200 (MFI = 640 and 1200) coupled to a strong expression of CD180 (MFI = 5300) was observed in the MZL group. A moderate expression of these three markers was observed in the LPL group. A threshold corresponding to MFI +/- 4 standard error was then calculated for each group (see table 1), and patients were categorized following the expression profile of these 3 markers. Table 1: threshold calculated from the average MFI and the associated standard error for each studied pathologies. CD148 CD180 CD200 MCL >980 <1500 <900 CLL <680 <1150 >500 MZL <1000 >2700 <2200 LPL 540 to 1350 500 to 1450 100 to 2700 In this cohort, the above described profiles correctly identified MCL cases with a specificity of 96% and a sensitivity of 65%, CLL cases with a specificity of 95% and a sensitivity of 79%, LPL cases with a specificity of 95% and a sensitivity of 31% and MZL cases with a specificity of 99% and a sensitivity of 52%. These results strongly suggest that the incorporation of these three markers CD148 CD180 and CD200 in addition of the routinely used flow cytometry panel can be helpful in a number of cases for which the diagnosis remains difficult. References: 1) Miguet et al. Leukemia 2013 2) Miguet et al. Journal of Proteome Research 2009 3) Palumbo et al. Leukemia Research 2009 Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 48 (5) ◽  
pp. 2295-2305
Author(s):  
Jiawei Zhang ◽  
Dandan Li ◽  
Rui Zhang ◽  
Peng Gao ◽  
Rongxue Peng ◽  
...  

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.


VASA ◽  
2014 ◽  
Vol 43 (3) ◽  
pp. 189-197 ◽  
Author(s):  
Yiqiang Zhan ◽  
Jinming Yu ◽  
Rongjing Ding ◽  
Yihong Sun ◽  
Dayi Hu

Background: The associations of triglyceride (TG) to high-density lipoprotein cholesterol ratio (HDL‑C) and total cholesterol (TC) to HDL‑C ratio and low ankle brachial index (ABI) were seldom investigated. Patients and methods: A population based cross-sectional survey was conducted and 2982 participants 60 years and over were recruited. TG, TC, HDL‑C, and low-density lipoprotein cholesterol (LDL-C) were assessed in all participants. Low ABI was defined as ABI ≤ 0.9 in either leg. Multiple logistic regression models were applied to study the association between TG/HDL‑C ratio, TC/HDL‑C ratio and low ABI. Results: The TG/HDL‑C ratios for those with ABI > 0.9 and ABI ≤ 0.9 were 1.28 ± 1.20 and 1.48 ± 1.13 (P < 0.0001), while the TC/HDL‑C ratios were 3.96 ± 1.09 and 4.32 ± 1.15 (P < 0.0001), respectively. After adjusting for age, gender, body mass index, obesity, current drinking, physical activity, hypertension, diabetes, lipid-lowering drugs, and cardiovascular disease history, the odds ratios (ORs) with 95 % confidence intervals (CIs) of low ABI for TG/HDL‑C ratio and TC/HDL‑C ratio were 1.10 (0.96, 1.26) and 1.34 (1.14, 1.59) in non-smokers. When TC was further adjusted, the ORs (95 % CIs) were 1.40 (0.79, 2.52) and 1.53 (1.21, 1.93) for TG/HDL‑C ratio and TC/HDL‑C ratio, respectively. Non-linear relationships were detected between TG/HDL‑C ratio and TC/HDL‑C ratio and low ABI in both smokers and non-smokers. Conclusions: TC/HDL‑C ratio was significantly associated with low ABI in non-smokers and the association was independent of TC, TG, HDL‑C, and LDL-C. TC/HDL‑C might be considered as a potential biomarker for early peripheral arterial disease screening.


Pneumologie ◽  
2012 ◽  
Vol 66 (06) ◽  
Author(s):  
N Kahn ◽  
A Rossler ◽  
K Hornemann ◽  
T Muley ◽  
A Warth ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document